Treamid
Identification
- Name
- Treamid
- Accession Number
- DB16365
- Description
Treamid, also known as bisamide derivative of dicarboxylic acid (BDDA), is a complexing agent that has been found to chelate metal ions, including calcium, copper, iron, magnesium, and zinc.1 This drug has shown regenerative properties and restoration of the function of various tissues and organs. It is has been investigated in the clinical trials of NCT04428593 (Study to Assess Safety, Tolerability and Pharmacokinetics of Treamid in Healthy Volunteers) and NCT04527354 (Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia) by PHARMENTERPRISES.
- Type
- Small Molecule
- Groups
- Investigational
- Synonyms
- BDDA
- Bisamide derivative of dicarboxylic acid
- XC268BG
- External IDs
- XC268BG
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
- Not Available
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
- Not Available
- Mechanism of action
In animal studies, treamid displays a positive effect on the capillaries of lungs, exhibits anti-fibrotic activity, and increases the number of endothelial progenitor cells in the lungs of animals with pulmonary fibrosis.1 Currently, the drug is being investigated against COVID-19.
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
References
- General References
- Skurikhin E, Nebolsin V, Widera D, Ermakova N, Pershina O, Pakhomova A, Krupin V, Pan E, Zhukova M, Novikov F, Sandrikina L, Morozov S, Kubatiev A, Dygai A: Antifibrotic and Regenerative Effects of Treamid in Pulmonary Fibrosis. Int J Mol Sci. 2020 Nov 8;21(21). pii: ijms21218380. doi: 10.3390/ijms21218380. [PubMed:33171668]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Coronavirus Disease 2019 (COVID‑19) / Pulmonary Fibrosis 1 1 Completed Treatment Syndrome, Metabolic 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created on December 17, 2020 23:41 / Updated on December 20, 2020 03:42